Thursday, February 04, 2010
Topics – Lack of Appetite and Loss of Weight – Canadian Virtual Hospice
Lack of Appetite and Loss of Weight
add your opinions
advanced cancer
,
appetite
,
palliative
,
weight loss
When Advanced Cancer Patients Won’t Eat: Family Member Responses
To read more:
add your opinions
advanced cancer
,
eating
,
family
,
food
,
palliative
Rare ovarian tumours: therapeutic strategies in 2010, national website observatory for rare ovarian cancers and delineation of referent centers-France
Note: ignore the small spelling errors in the article as it was translated from French to English
add your opinions
advanced cancer
,
awards voice spirit cancer survivor ovarian
,
France
,
rare
,
rare ovarian tumors
,
strategies
Peritoneal-based Malignancies and Their Treatment. [Ann Acad Med Singapore. 2010] - PubMed result
Conclusion: It is important to recognise the role of and indications for CRS and HIPEC
MicroRNAs in ovarian carcinomas -- Dahiya and Morin 17 (1): F77 -- Endocrine-Related Cancer
(abstract) FOCUS REVIEW
MicroRNAs in ovarian carcinomas
Neetu Dahiya1 and Patrice J Morin1,2
1 Laboratory of Cellular and Molecular Biology, National Institute on Aging, NIH Biomedical Research Center, 251 Bayview Boulevard, Suite 100, Room 6C228, Baltimore, Maryland 21224, USA
2 Department of Pathology, Johns Hopkins Medical Institutions, Baltimore, Maryland 21287, USA
add your opinions
microRNA
,
molecular
,
ovarian cancer
Phase 1Trial Bi-shRNA-furin and Granulocyte Macrophage Colony Stimulating Factor (GMCSF) Augmented Autologous Tumor Cell Vaccine for Advanced Cancer
Trial of Bi-shRNA-furin and Granulocyte Macrophage Colony Stimulating Factor (GMCSF) Augmented Autologous Tumor Cell Vaccine for Advanced Cancer - Full Text View - ClinicalTrials.gov
In Research: Yale Makes Possible Breakthrough in Ovarian Cancer Treatment | NBC Connecticut
"Genetic researchers prevent genes from performing their function, "knocking down" the gene, by inserting small interfering RNA (siRNA) molecules into the cells. The next steps in the team's research will be to examine the effect of siRNA in ovarian cancer samples in the lab, and to test the technique on mice."
add your opinions
genes
,
invasive ovarian cancers
,
RNA
EPGM-Munich - Expert Practice in Gynecologic Oncology - free access
There are a number of slide presentations (free full access)
add your opinions
gynecologic oncology
,
presentations
,
slides
Muir-Torre syndrome-is it really a new syndrome? Am J Dermapathology
Note: that there is an overlap here with Lynch Syndrome
"This syndrome is defined as the coexistence of sebaceous adenomas, sebaceus carcinomas, keratoacanthomas, and pedunculated tumors, some with lobulated structure. The cutaneous involvement (sebaceous gland tumor) is associated with at least a single internal malignancy; mostly colonorectal or genitourinary malignancies."
Medical News: Hidden Dangers of Herbal Meds Reviewed - in Primary Care, Alternative Medicine from MedPage Today
discusses some of the negative interactions
add your opinions
complicatons
,
drug interactions
,
herbal remedies
Wednesday, February 03, 2010
Deadline February 28th: Nominations: Becoming a Member
Ideal Candidates for the NCI Director's Consumer Liaison Group:
Ideal candidates must:
1. have first-hand knowledge of the cancer experience;
2. be affiliated with a cancer-related constituency; and
3. possess relevant non-scientific skills and perspectives that will allow them to help improve research outcomes by identifying new approaches, promoting innovation, recognizing unforeseen risks or barriers, and identifying unintended consequences that could result from NCI decisions.
Wait Times For Medical Care: How The US Actually Measures Up - Better Health
Note: ACOR ovarian cancer members - the report will be in the archives - Commonwealth Fund
add your opinions
Canada
,
cancer oncology alternatives complimentary medicine Canada U.S.
,
Commonweath Fund
,
comparisons
,
Europe
,
international
,
wait times
Subscribe to:
Posts
(
Atom
)